Recursion Pharmaceuticals Stock (NASDAQ:RXRX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$6.40

52W Range

$5.04 - $15.74

50D Avg

$6.64

200D Avg

$8.54

Market Cap

$1.89B

Avg Vol (3M)

$4.81M

Beta

0.80

Div Yield

-

RXRX Company Profile


Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

500

IPO Date

Apr 16, 2021

Website

RXRX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
License and Service$43.88M$39.68M$10.00M
Grant$699.00K$162.00K$178.00K

Fiscal year ends in Dec 23 | Currency in USD

RXRX Financial Summary


Dec 23Dec 22Dec 21
Revenue$44.58M$39.68M$10.00M
Operating Income$-350.06M$-245.73M$-182.78M
Net Income$-328.07M$-239.42M$-178.07M
EBITDA$-350.06M$-245.73M$-182.78M
Basic EPS$-1.58$-1.36$-1.42
Diluted EPS$-1.58$-1.36$-1.42

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 09, 24 | 8:25 AM
Q1 24May 09, 24 | 10:53 PM
Q4 23Feb 27, 24 | 11:27 PM

Peer Comparison


TickerCompany
SANASana Biotechnology, Inc.
XFORX4 Pharmaceuticals, Inc.
CNSPCNS Pharmaceuticals, Inc.
CWBRCohBar, Inc.
VECTVectivBio Holding AG
DAWNDay One Biopharmaceuticals, Inc.
RLAYRelay Therapeutics, Inc.
ABSIAbsci Corporation
AVROAVROBIO, Inc.
INZYInozyme Pharma, Inc.
EFTReFFECTOR Therapeutics, Inc.
AFMDAffimed N.V.
IMMXImmix Biopharma, Inc.
ABOSAcumen Pharmaceuticals, Inc.
OCEAOcean Biomedical, Inc.
HEPAHepion Pharmaceuticals, Inc.
ENVBEnveric Biosciences, Inc.